Ramsay Health Care suspends dividend and raises capital

Ramsay Health Care Limited (ASX: RHC) shares are in a trading halt after the company announced a capital raising.

Shares in Australia's largest hospital operator Ramsay Health Care Limited (ASX: RHC) were placed in a trading halt earlier today, pending details of a capital raising.

a woman

Capital raising and dividend suspension

Ramsay is looking to undertake an equity raising worth up to $1.4 billion, consisting of $1.2 billion in an underwritten institutional placement of shares and $200 million in a non-underwritten share purchase plan.

The institutional placement will be conducted at $56.00, representing a 12.9% discount from Ramsay's last closing price of $64.29 and will see approximately 21.4 million new shares being issued. Following the completion of the placement, Ramsay will be looking to raise up to $200 million from retail shareholders through a share purchase plan.

In addition to the capital raising, Ramsay announced that due to the impact of the coronavirus pandemic on cash flow, the company has temporarily suspended payment of its ordinary share dividends. However, Ramsay did note that it will continue to pay dividends on its Convertible Adjustable Rate Equity Securities (CARES).

Why is Ramsay raising capital?

In an announcement to the market this morning, Ramsay cited that the suspension of elective procedures due to COVID-19 has led to an uncertain operating environment. As a result, the equity raising will provide Ramsay with financial flexibility and security in the current environment, whilst also allowing the company to take advantage of any future growth opportunities.

Ramsay has operations in more than 500 locations across 11 countries. As a result of the coronavirus pandemic, respective governments in each of Ramsay's major operating regions deferred elective procedures in private hospitals in order to support public health systems.

Last month, Ramsay withdrew its earnings guidance for FY20, citing the uncertain duration and impact of the coronavirus pandemic. With elective surgeries being the main source of revenue for private operators like Ramsay, the Australian government recently provided private hospitals with a $1.3 billion viability guarantee. However, with some elective surgeries being resumed, the income that private hospitals receive will reduce the funding flow from the government.

Should you buy?

Restrictions on elective and non-urgent surgeries will be partially lifted by the federal government on 27 April. As a result, post-cancer, hip, knee, and other joint replacement surgeries will be able to go ahead in addition to IVF procedures.

The Ramsay share price has tanked more than 20% from its high in mid-February of $80.93. Ramsay shares will remain in a trading halt until the commencement of normal trading on Thursday, 24 April 2020.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »